Literature DB >> 6307866

Chronic liver disease: the detection and characterization of circulating immune complexes.

S E Brown, M W Steward, L Viola, C R Howard, I M Murray-Lyon.   

Abstract

Circulating immune complexes containing IgG, IgM and hepatitis B surface antigen (HBsAg) in sera from groups of patients with various liver diseases were detected by both the C1q and conglutinin solid phase assays. Elevated levels of antigen non-specific immune complexes were observed in sera from all groups and complexes containing IgG were present to a greater extent than were IgM-containing complexes. Higher levels of complexes were generally obtained using the conglutinin assay than the C1q assay and the two assays were shown to preferentially bind complexes of different size ranges and antigen-antibody ratios. Only sera from HBsAg-positive patients had complexes containing HBsAg, and although serum HBsAg titres and levels of HBsAg-containing complexes were correlated, the correlation coefficient was low. The mean levels of immune complexes and the frequency of positive sera varied between different disease categories, but there was little correlation between levels of the three types of complexes detected by the two tests. Assay of immune complexes in sequential serum samples from an individual patient revealed considerable variation in the levels of the three complex types, demonstrating that the measurement of complexes in single serum samples is of limited value in assessing the potential significance of circulating immune complexes in hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307866      PMCID: PMC1454316     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q.

Authors:  F C Hay; L J Nineham; I M Roitt
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Incidence and meaning of the "e" determinant among hepatitis-B-antigen positive patients with acute and chronic liver diseases. Report from the Copenhagen Hepatitis Acuta Programme.

Authors:  J O Nielsen; O Dietrichson; E Juhl
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

4.  Role of the liver in controlling the immunogenicity of commensal bacteria in the gut.

Authors:  H C Thomas; R N McSween; R G White
Journal:  Lancet       Date:  1973-06-09       Impact factor: 79.321

5.  Differences in immune elimination in inbred mice. The role of low affinity antibody.

Authors:  J H Alpers; M W Steward; J F Soothill
Journal:  Clin Exp Immunol       Date:  1972-09       Impact factor: 4.330

6.  Clq: rapid purification method for preparation of monospecific antisera and for biochemical studies.

Authors:  K Yonemasu; R M Stroud
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

7.  The immunopathological significance of the heterogeneity of antibody affinity.

Authors:  J F Soothill; M W Steward
Journal:  Clin Exp Immunol       Date:  1971-08       Impact factor: 4.330

Review 8.  Immunopathology of viral hepatitis in man.

Authors:  W D Reed; A L Eddleston; R Williams
Journal:  Prog Med Virol       Date:  1974

9.  Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q.

Authors:  U E Nydegger; P H Lambert; H Gerber; P A Miescher
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

10.  Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation.

Authors:  M Mannik; M P Arend; A P Hall; B C Gilliland
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

View more
  10 in total

Review 1.  The humoral immune response in acute and chronic hepatitis B virus infection.

Authors:  D R Milich; M Sallberg; T Maruyama
Journal:  Springer Semin Immunopathol       Date:  1995

2.  The serology of chronic hepatitis B infection revisited.

Authors:  T Maruyama; A McLachlan; S Iino; K Koike; K Kurokawa; D R Milich
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

3.  IgG subclasses in circulating immune complexes with hepatitis B e antigen in chronic hepatitis B.

Authors:  M Sällberg; H Norder; G Lindh; L O Magnius
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

4.  Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus.

Authors:  K Madalinski; B Burczynska; K H Heermann; A Uy; W H Gerlich
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

5.  Hepatitis B surface antigen containing immune complexes occur in seronegative hepatocellular carcinoma patients.

Authors:  S E Brown; C R Howard; M W Steward; A B Ajdukiewicz; H C Whittle
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

6.  IgA containing circulating immune complexes and IgA anti-single stranded DNA antibodies in patients with obstructive jaundice.

Authors:  G Ohshio; F Furukawa; K Sekita; T Manabe; T Tobe; Y Hamashima
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

7.  IgG subclass composition of antibodies to HBsAg in circulating immune complexes from patients with hepatitis B virus infections.

Authors:  S Rath; M E Devey
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

8.  Adaptive immune defense prevents Bartonella persistence upon trans-placental transmission.

Authors:  Lena K Siewert; Christoph Dehio; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2022-05-17       Impact factor: 6.823

9.  Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

10.  Antibody responses during hepatitis B viral infection.

Authors:  Stanca M Ciupe; Ruy M Ribeiro; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2014-07-31       Impact factor: 4.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.